President Biden took a groundbreaking step in proposing to cover GLP-1 obesity medications under Medicare and Medicaid in November. But on Friday, his administration announced that Wegovy, one of these drugs, would be subject to price controls. This is a surefire way to crush innovation and discourage new entrants to this important new class of medicines that could help millions of Americans.
GLP-1s, or glucagon-like peptide-1 receptor agonists, are safe and effective. They not only help people lose weight but also reduce the risk of diabetes, cardiovascular disease, and potentially fight addiction to alcohol, illicit drugs, and opioids — key priorities from President-elect Trump’s first term that also have huge potential to lower health care costs. They can play a substantial role in Trump’s Make America Healthy Again (MAHA) initiative, and potentially help rein in excessive government spending as the Department of Government Efficiency (DOGE) intends.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
